Core Viewpoint - AptarGroup, Inc. demonstrates strong financial health and commitment to shareholder value through a nearly 7% increase in its quarterly dividend, despite a recent stock price decrease [2][6]. Financial Performance - The company has increased its quarterly dividend by nearly 7%, reflecting robust financial health and a commitment to shareholder value [2][6]. - Aptar's market capitalization is approximately $8.9 billion, with a trading volume of 356,108 shares, indicating a significant presence in the industry [5]. Analyst Coverage - KeyBanc has initiated coverage on Aptar with an Overweight rating, suggesting potential for growth and value in the company's stock [3][6]. - At the time of the coverage initiation, Aptar's stock was priced at $135.22, indicating analysts' positive outlook aligns with the company's recent dividend increase [3]. Insider Activity - The sale of 1,167 shares by Chief Human Resources Officer Vinczeller Shiela at approximately $137.97 per share is notable, yet she retains 25,134 shares, indicating continued confidence in the company's prospects [4][6]. Market Position - The stock's 52-week range shows a high of $178.03 and a low of $130.85, reflecting its volatility, but the recent dividend increase and positive analyst coverage suggest a stable outlook for the company [5].

PresentationMarry SkafidasSenior Vice President of Investor Relations & Communications Good morning. My name is Mary Skafidas. I head up Investor Relations and Communications for Aptar, and I'm absolutely delighted to welcome you to Aptar's Investor Day 2025. So I am just going to -- first stop on our Investor Day tour are, of course, our disclosures page. This is for our General Counsel. It's up there. Okay. I just want to take a few seconds to give you some background on Aptar for those of you that might ...

Key Takeaways ATR raised its quarterly dividend to 48 cents per share, payable Nov. 13, 2025, to its holders on Oct. 23.The hike lifts ATR's annualized dividend to $1.92 and its dividend yield to 1.4%.ATR has returned over $1B to its shareholders in five years via dividends and buybacks.AptarGroup, Inc. (ATR) has announced a nearly 7% hike in quarterly dividend payout, keeping the company on track to achieve its 32nd consecutive year of annual dividend increase. This is in sync with its long-standing commit ...

AptarGroup (NYSE:ATR) 2025 Investor Day September 09, 2025 09:00 AM ET Company ParticipantsMary Skafidas - Senior VP - IRStephan Tanda - President & CEOGael Touya - President - Aptar PharmaAlex Theodorakis - President - Pharma PrescriptionMarc Prieur - President - Aptar BeautyHeidi Tlili - President - Aptar ClosuresVanessa Kanu - EVP & CFOGeorge Staphos - Managing DirectorConference Call ParticipantsGhansham Panjabi - Senior Research AnalystMatt Larew - Research Analyst - HealthcareAnna Snopkowski - Equity ...

Investor Day September 9, 2025 Welcome Mary Skafidas, Senior Vice President, Investor Relations and Communications 2 Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs and assumptions in light of information currently available to managem ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Increases Quarterly Dividend by Nearly 7% Signaling Continued Momentum and Long-Term Strength. ...

Core Viewpoint - The FDA upheld the De Novo denial for CytoSorbents' DrugSorb-ATR device but found no safety issues, proposing a potential path forward for market authorization [2][3]. Regulatory Status - On August 14, 2025, the FDA issued a decision following an appeal regarding the De Novo application for DrugSorb-ATR, which was initially denied on April 25, 2025, due to the need for additional information [2][7]. - The FDA's appeal decision confirmed the device's safety but maintained the denial, indicating that further information is required to support the desired label indication [2][3]. - The FDA suggested a potential path forward for market authorization and noted that the company could appeal to a higher level within the FDA [2][7]. Company Insights - CytoSorbents Corporation specializes in blood purification technologies aimed at treating life-threatening conditions in intensive care and cardiac surgery [4][5]. - The company’s lead product, CytoSorb®, is already approved in the EU and has been used in nearly 300,000 devices globally [5]. - DrugSorb-ATR is designed to reduce perioperative bleeding in high-risk surgeries for patients on blood thinners, having received two FDA Breakthrough Device Designations [7][9]. Market Need - There is a significant need for solutions addressing perioperative bleeding in patients undergoing urgent coronary artery bypass graft (CABG) surgery, particularly those on ticagrelor [3][4]. - The technology aims to mitigate risks associated with blood thinners, which are increasingly common among patients, thereby addressing a critical issue faced by surgeons and patients alike [3][4].

Core Viewpoint - AptarGroup reported strong Q2 2025 earnings, with adjusted EPS of $1.66 exceeding estimates and GAAP revenue of $966 million surpassing forecasts, driven by margin improvement and sales growth in key segments despite macroeconomic uncertainties [1][2][5]. Financial Performance - Adjusted EPS for Q2 2025 was $1.66, up 18% from $1.41 in Q2 2024 [2] - GAAP revenue reached $966 million, a 6% increase from $910 million in the prior year [2] - Adjusted EBITDA was $218 million, reflecting a 13% year-over-year growth [2] - Adjusted EBITDA margin improved to 22.6%, up 1.4 percentage points from 21.2% in Q2 2024 [2] - Free cash flow was reported at $65.8 million, down 12.7% from $75.4 million in the previous year [2] Company Overview and Strategic Focus - AptarGroup specializes in packaging and dispensing systems for pharmaceuticals, beauty, food, and beverages, with products including nasal sprays and closures for food containers [3] - The company prioritizes innovation, regional manufacturing, and sustainability, focusing on R&D for advanced packaging solutions [4] Segment Performance - The Pharma segment accounted for 46% of sales, with a 7% revenue increase year-over-year and an adjusted EBITDA margin of 35.4% [5][8] - The Beauty segment saw a 4% revenue rise, with an adjusted EBITDA margin of 14.1% [6] - The Closures segment reported an 8% sales growth, achieving an adjusted EBITDA margin of 16.9% [7][8] Innovation and Product Development - New product launches included proprietary drug delivery systems and recyclable dispensers, with a focus on localizing supply chains to mitigate trade risks [10] - The Active Material Science division experienced an 11% increase in core sales, driven by demand for advanced drug delivery solutions [5] Capital Allocation and Shareholder Returns - The company returned $100 million to shareholders through buybacks and dividends, with year-to-date returns totaling $210 million [11] - Ongoing investments in plant and equipment highlight the company's commitment to expansion and operational improvement [11] Outlook - For Q3 2025, management projects adjusted EPS between $1.53 and $1.61, indicating flat performance compared to Q3 2024 [12] - Anticipated challenges include normalizing sales of naloxone and elevated cough and cold inventory in Europe [12] - The company continues to focus on sustainable packaging solutions to meet industry demands [13]

Company Overview - AptarGroup is a global supplier of innovative dispensing, sealing, and active packaging solutions for various markets including beauty, personal care, home care, prescription drugs, consumer health care, injectables, food, and beverages [12] - The company manufactures products such as dispensing pumps, closures, aerosol valves, and elastomeric primary packaging components, with facilities located in North America, Europe, Asia, and South America [12] Investment Analysis - AptarGroup currently holds a Zacks Rank of 3 (Hold) and has a VGM Score of B, indicating a solid position in the market [13] - The company is projected to experience year-over-year earnings growth of 4.3% for the current fiscal year, supported by upward revisions in earnings estimates from three analysts in the last 60 days [13] - The Zacks Consensus Estimate for AptarGroup's earnings has increased by $0.01 to $5.88 per share, with an average earnings surprise of +8.3% [13][14]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 1-11846 AptarGroup, Inc. Delaware 36-3853103 (State of Incorporation) (I.R.S. Employer Identification No.) 265 EXCHANGE DRIVE, ...